277 related articles for article (PubMed ID: 36891298)
1. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
[TBL] [Abstract][Full Text] [Related]
2. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
3. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
Front Genet; 2023; 14():1096783. PubMed ID: 36911392
[No Abstract] [Full Text] [Related]
4. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
6. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.
Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M
Front Genet; 2022; 13():951311. PubMed ID: 36406130
[No Abstract] [Full Text] [Related]
7. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma.
Zeng C; Liu Y; He R; Lu X; Dai Y; Qi G; Liu J; Deng J; Lu W; Jin J; Liu Q
Front Genet; 2022; 13():935056. PubMed ID: 36092903
[No Abstract] [Full Text] [Related]
9. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
[TBL] [Abstract][Full Text] [Related]
10. The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in Prostate Cancer Treatment.
Sun JX; An Y; Xiang JC; Xu JZ; Hu J; Wang SG; Xia QD
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686409
[TBL] [Abstract][Full Text] [Related]
11. The Senescence-Related Signature Predicts Prognosis and Characterization of Tumor Microenvironment Infiltration in Pancreatic Cancer.
Hua H; Zheng C; Fan J; Li X; Xie W; Chen J; Yu C
Biomed Res Int; 2022; 2022():1916787. PubMed ID: 36518628
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
14. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
15. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
16. Machine Learning-based Development and Validation of a Cell Senescence Predictive and Prognostic Signature in Intrahepatic Cholangiocarcinoma.
Yang R; Sun F; Shi Y; Wang H; Fan Y; Wu Y; Fan R; Wu S; Sun L
J Cancer; 2024; 15(9):2810-2828. PubMed ID: 38577599
[No Abstract] [Full Text] [Related]
17. A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer.
Zhang C; Zeng C; Xiong S; Zhao Z; Wu G
Sci Rep; 2022 Nov; 12(1):18688. PubMed ID: 36333388
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
19. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
20. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]